NCT04472767 - Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

June 1, 2026

Study Completion Date

September 1, 2027

Conditions

Hepatocellular CarcinomaHCC

Interventions

DRUG

Nivolumab

Given IV

DRUG

Ipilimumab

Given IV

DRUG

Cabozantinib

Given PO

PROCEDURE

Transarterial Chemoembolization

TACE treatment will be administered using either the DEB-TACE or cTACE modality in a series of up to 3 individual procedures within the 9-12 weeks following Day 21 (= cycle 1 day 21) of a patient's first infusion of nivolumab/ipilimumab. The first TACE treatment should start no more than 7 working days after being cycle 1 day 21.

Trial Locations (1)

92868

RECRUITING

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange